CoChat

Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease

Watson, Kathleen T., Wroolie, Tonita E., Tong, Gabby, Foland-Ross, Lara C., Frangou, Sophia, Singh, Manpreet, McIntyre, Roger S., Roat-Shumway, Siena, Myoraku, Alison, Reiss, Allan L., Rasgon, Natalie L. · 2019 · Behavioural Brain Research
Cited by 134

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

&NA; Insulin resistance (IR) is a metabolic state preceding development of type 2 diabetes (DM2), cardiovascular disease, and neurodegenerative disorders, including Alzheimer's Disease (AD). Liraglutide, a glucagon‐like peptide‐1 (GLP) agonist, is an insulin‐sensitizing agent with neuroprotective properties, as shown in animal studies. The purpose of this double‐blinded, placebo‐controlled study was to examine the neural effects of administration of liraglutide in cognitively normal late middle‐aged individuals with subjective cognitive complaints (half of subjects had family history of AD). Seed‐based resting state connectivity using functional magnetic resonance imaging (fMRI) was conducted before and after 12 weeks of liraglutide treatment or placebo. Neuropsychological testing was conducted before and after treatment to determine whether there were any potential behavioral correlates to neural changes. Results: At baseline (time point 1), higher fasting plasma glucose (FPG) was associated with decreased connectivity between bilateral hippocampal and anterior medial frontal structures. At time point 2, we observed significant improvement in intrinsic connectivity within the default mode network (DMN) in the active group relative to placebo. There were no detectable cognitive differences between study groups after this duration of treatment. To our knowledge, this is the first placebo‐controlled study to report neural effects of liraglutide in a middle‐aged population with subjective cognitive complaints. Larger and longer duration studies are warranted to determine whether liraglutide has neuroprotective benefits in individuals at risk for AD. HighlightsLiraglutide improves intrinsic connectivity within default mode network.Baseline fasting glucose associated with greater connectivity.No cognitive differences found after liraglutide treatment compared to placebo.Liraglutide may be neuroprotective in individuals at risk for Alzheimer's Disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbr.2018.08.006

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Watson, K. T., Wroolie, T. E., Tong, G., Foland-Ross, L. C., Frangou, S., Singh, M., McIntyre, R. S., Roat-Shumway, S., Myoraku, A., Reiss, A. L., & Rasgon, N. L.
Venue
Behavioural Brain Research
Publisher
Elsevier BV
Published
2019-01
Volume
356
Pages
271-278
ISSN
0166-4328 (ISSN-L)
OpenAlex
W2887818584
Cited by
134
References
12
FWCI
5.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.